JP2014527061A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014527061A5 JP2014527061A5 JP2014527322A JP2014527322A JP2014527061A5 JP 2014527061 A5 JP2014527061 A5 JP 2014527061A5 JP 2014527322 A JP2014527322 A JP 2014527322A JP 2014527322 A JP2014527322 A JP 2014527322A JP 2014527061 A5 JP2014527061 A5 JP 2014527061A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- imidazol
- carbonyl
- hcv
- biphenylyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 *C(N(C(CCC1)C1C1)C1c1ncc(-c2ccc3-c4cc(-c5cnc(C(CC6C7CCC6)N7C(*)=O)[n]5)ccc4-c3c2)[n]1)=O Chemical compound *C(N(C(CCC1)C1C1)C1c1ncc(-c2ccc3-c4cc(-c5cnc(C(CC6C7CCC6)N7C(*)=O)[n]5)ccc4-c3c2)[n]1)=O 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161526798P | 2011-08-24 | 2011-08-24 | |
| US61/526,798 | 2011-08-24 | ||
| US201161529358P | 2011-08-31 | 2011-08-31 | |
| US61/529,358 | 2011-08-31 | ||
| US201261617813P | 2012-03-30 | 2012-03-30 | |
| US61/617,813 | 2012-03-30 | ||
| PCT/US2012/052216 WO2013028953A1 (en) | 2011-08-24 | 2012-08-24 | Combination treatments for hepatitis c |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017083252A Division JP2017165746A (ja) | 2011-08-24 | 2017-04-20 | Ｃ型肝炎の組合せ治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014527061A JP2014527061A (ja) | 2014-10-09 |
| JP2014527061A5 true JP2014527061A5 (https=) | 2015-10-08 |
Family
ID=47746891
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014527322A Pending JP2014527061A (ja) | 2011-08-24 | 2012-08-24 | Ｃ型肝炎の組合せ治療 |
| JP2017083252A Pending JP2017165746A (ja) | 2011-08-24 | 2017-04-20 | Ｃ型肝炎の組合せ治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017083252A Pending JP2017165746A (ja) | 2011-08-24 | 2017-04-20 | Ｃ型肝炎の組合せ治療 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20140234253A1 (https=) |
| EP (1) | EP2747569A4 (https=) |
| JP (2) | JP2014527061A (https=) |
| KR (1) | KR20140065427A (https=) |
| CN (1) | CN103917095A (https=) |
| AU (1) | AU2012298750A1 (https=) |
| BR (1) | BR112014004182A2 (https=) |
| CA (1) | CA2845321A1 (https=) |
| CL (1) | CL2014000428A1 (https=) |
| CO (1) | CO6890100A2 (https=) |
| CR (1) | CR20140086A (https=) |
| EA (1) | EA201490254A1 (https=) |
| HK (1) | HK1198869A1 (https=) |
| IL (1) | IL230844A0 (https=) |
| MX (1) | MX2014002171A (https=) |
| PH (1) | PH12014500386A1 (https=) |
| SG (1) | SG2014010490A (https=) |
| WO (1) | WO2013028953A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201290089A1 (ru) | 2009-09-04 | 2012-09-28 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | Химические соединения |
| BR112014003556A2 (pt) * | 2011-08-17 | 2017-03-21 | Glaxosmithkline Llc | método de tratamento de vírus, e, composição farmacêutica |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| SE1450131A1 (sv) | 2011-10-21 | 2014-05-07 | Abbvie Inc | DAA-kombinationsbehandling (t.ex. med ABT-072 eller ABT-333)för användning vid behandling av HCV |
| DE112012002748T5 (de) | 2011-10-21 | 2014-07-31 | Abbvie Inc. | Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon |
| US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| AU2014250762A1 (en) | 2013-04-12 | 2015-10-29 | Achillion Pharmaceuticals, Inc. | Highly active nucleoside derivative for the treatment of HCV |
| US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
| US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| JP6333372B2 (ja) * | 2013-07-09 | 2018-05-30 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃ型肝炎ウイルス阻害剤の組み合わせ |
| US9775831B2 (en) | 2013-07-17 | 2017-10-03 | Bristol-Myers Squibb Company | Combinations comprising biphenyl derivatives for use in the treatment of HCV |
| WO2015096674A1 (zh) * | 2013-12-23 | 2015-07-02 | 南京圣和药业股份有限公司 | 丙型肝炎病毒抑制剂及其应用 |
| US9512108B2 (en) * | 2013-12-31 | 2016-12-06 | Nanjing Sanhome Pharmaceutical Co., Ltd. | 9,9,10,10-Tetrafluoro-9,10-dihydrophenanthrene hepatitis C virus inhibitor and application thereof |
| CN106279122A (zh) * | 2014-01-21 | 2017-01-04 | 杭州普晒医药科技有限公司 | 一种化合物的盐及晶型或无定型物、其制备方法、含有它们的药物组合物和用途 |
| US20170312297A1 (en) * | 2014-11-10 | 2017-11-02 | Glaxosmithkline Intellectual Property (No. 2) Limited | Long Acting Pharmaceutical Compositions For Hepatitis C |
| MA41812A (fr) * | 2015-03-27 | 2018-01-30 | Janssen Pharmaceuticals Inc | Procédés et intermédiaires pour la préparation d'un inhibiteur de protéase macrocyclique du vhc |
| US10617675B2 (en) | 2015-08-06 | 2020-04-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EA201892448A1 (ru) | 2016-04-28 | 2019-06-28 | Эмори Юниверсити | Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения |
| CN110693887B (zh) * | 2019-05-17 | 2022-06-17 | 歌礼药业（浙江）有限公司 | 包含索磷布韦和拉维达韦的片剂及其制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100158862A1 (en) * | 2006-08-11 | 2010-06-24 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US8303944B2 (en) * | 2006-08-11 | 2012-11-06 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8329159B2 (en) * | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7704992B2 (en) * | 2008-02-13 | 2010-04-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2010042834A1 (en) * | 2008-10-09 | 2010-04-15 | Anadys Pharmaceuticals, Inc. | A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds |
| US8729077B2 (en) * | 2008-11-28 | 2014-05-20 | Glaxosmithkline Llc | Anti-viral compounds, compositions, and methods of use |
| CN102271699A (zh) * | 2009-01-07 | 2011-12-07 | 西尼克斯公司 | 用于治疗hcv和hiv感染的环孢菌素衍生物 |
| PT3309157T (pt) * | 2009-05-13 | 2019-12-02 | Gilead Pharmasset Llc | Compostos antivirais |
| EA201290089A1 (ru) * | 2009-09-04 | 2012-09-28 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | Химические соединения |
| US8415374B2 (en) * | 2009-10-12 | 2013-04-09 | Bristol-Myers Squibb Company | Combinations of hepatitis C virus inhibitors |
| US8377980B2 (en) * | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| KR20120118008A (ko) * | 2009-12-18 | 2012-10-25 | 아이데닉스 파마슈티칼스, 인코포레이티드 | 5,5-융합 아릴렌 또는 헤테로아릴렌 간염 ｃ 바이러스 억제제 |
| US20120070411A1 (en) * | 2010-09-22 | 2012-03-22 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
-
2012
- 2012-08-24 PH PH1/2014/500386A patent/PH12014500386A1/en unknown
- 2012-08-24 EA EA201490254A patent/EA201490254A1/ru unknown
- 2012-08-24 US US14/240,420 patent/US20140234253A1/en not_active Abandoned
- 2012-08-24 AU AU2012298750A patent/AU2012298750A1/en not_active Abandoned
- 2012-08-24 CA CA2845321A patent/CA2845321A1/en not_active Abandoned
- 2012-08-24 SG SG2014010490A patent/SG2014010490A/en unknown
- 2012-08-24 WO PCT/US2012/052216 patent/WO2013028953A1/en not_active Ceased
- 2012-08-24 JP JP2014527322A patent/JP2014527061A/ja active Pending
- 2012-08-24 HK HK14112612.7A patent/HK1198869A1/xx unknown
- 2012-08-24 KR KR1020147007736A patent/KR20140065427A/ko not_active Withdrawn
- 2012-08-24 BR BR112014004182A patent/BR112014004182A2/pt not_active IP Right Cessation
- 2012-08-24 CN CN201280052257.0A patent/CN103917095A/zh active Pending
- 2012-08-24 MX MX2014002171A patent/MX2014002171A/es unknown
- 2012-08-24 EP EP12826268.0A patent/EP2747569A4/en not_active Withdrawn
-
2014
- 2014-02-06 IL IL230844A patent/IL230844A0/en unknown
- 2014-02-21 CL CL2014000428A patent/CL2014000428A1/es unknown
- 2014-02-24 CR CR20140086A patent/CR20140086A/es unknown
- 2014-02-26 CO CO14040944A patent/CO6890100A2/es unknown
-
2017
- 2017-04-20 JP JP2017083252A patent/JP2017165746A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014527061A5 (https=) | ||
| AU2014239563B2 (en) | Combination of two antivirals for treating hepatitis C | |
| US8415374B2 (en) | Combinations of hepatitis C virus inhibitors | |
| US20130072528A1 (en) | Methods for Treating HCV | |
| ES2654109T3 (es) | Combinación de agentes antivirales de acción directa y ribavirina para tratar pacientes con el VHC | |
| CA2942823C (en) | Methods for treating hcv | |
| JP2017165746A (ja) | Ｃ型肝炎の組合せ治療 | |
| EP2773342A1 (en) | Compositions useful for the treatment of viral diseases | |
| US20150011481A1 (en) | Methods for Treating HCV | |
| US20130172240A1 (en) | Methods for treating hcv | |
| AU2015240753B2 (en) | Methods for treating HCV | |
| MX2014015942A (es) | Tratamiento de combinacion con abt-450 y ritonavir y e. g. abt-072 y/o abt-333 para utilizarse en el tratamiento del vhc. | |
| US20170360783A1 (en) | Methods for Treating HCV | |
| US20170151238A1 (en) | Methods for Treating HCV | |
| US20200330460A1 (en) | Methods for Treating HCV | |
| EP3437643A1 (en) | Methods for treating hcv | |
| EP3360555A1 (en) | Methods for treating hcv | |
| HK40004326A (en) | Methods for treating hcv | |
| WO2016134058A1 (en) | Combinations useful to treat hepatitis c virus |